Trial · NCT04223856
Adverse events620
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 620
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Enfortumab Vedotin + Pembrolizumab | 106 | 440 | 168 |
| other | Anaemia | Blood and lymphatic system disorders | Standard of Care | 255 | 433 | 362 |
| other | Leukopenia | Blood and lymphatic system disorders | Enfortumab Vedotin + Pembrolizumab | 16 | 440 | 25 |
| other | Leukopenia | Blood and lymphatic system disorders | Standard of Care | 47 | 433 | 91 |
| other | Neutropenia | Blood and lymphatic system disorders | Enfortumab Vedotin + Pembrolizumab | 43 | 440 | 70 |
| other | Neutropenia | Blood and lymphatic system disorders | Standard of Care | 178 | 433 | 360 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Enfortumab Vedotin + Pembrolizumab | 19 | 440 | 21 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Standard of Care | 147 | 433 | 266 |
| other | Tinnitus | Ear and labyrinth disorders | Enfortumab Vedotin + Pembrolizumab | 6 | 440 | 6 |
| other | Tinnitus | Ear and labyrinth disorders | Standard of Care | 29 | 433 | 31 |
| other | Hypothyroidism | Endocrine disorders | Enfortumab Vedotin + Pembrolizumab | 45 | 440 | 47 |
| other | Hypothyroidism | Endocrine disorders | Standard of Care | 3 | 433 | 3 |
| other | Cataract | Eye disorders | Enfortumab Vedotin + Pembrolizumab | 22 | 440 | 23 |
| other | Cataract | Eye disorders | Standard of Care | 1 | 433 | 1 |
| other | Dry eye | Eye disorders | Enfortumab Vedotin + Pembrolizumab | 50 | 440 | 52 |
| other | Dry eye | Eye disorders | Standard of Care | 5 | 433 | 5 |
| other | Lacrimation increased | Eye disorders | Enfortumab Vedotin + Pembrolizumab | 36 | 440 | 42 |
| other | Lacrimation increased | Eye disorders | Standard of Care | 2 | 433 | 2 |
| other | Vision blurred | Eye disorders | Enfortumab Vedotin + Pembrolizumab | 26 | 440 | 28 |
| other | Vision blurred | Eye disorders | Standard of Care | 5 | 433 | 5 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04223856/events